American Regent vs. Accord Healthcare: Selenious Acid Patent Litigation Consolidated

Case Overview

Introduction: A Single Filing Becomes a Multi-Front Patent War

On December 13, 2024, American Regent, Inc. (ARI) launched a coordinated patent infringement offensive across the pharmaceutical generics landscape — filing twelve simultaneous lawsuits in the District of New Jersey targeting some of the industry’s most prominent generic drug manufacturers. Case No. 2:24-cv-11108, ARI’s action against Accord Healthcare, Ltd., represents one critical front in what rapidly evolved into one of the most significant trace element composition patent disputes of the year.

Within 21 days of filing, the case was consolidated into the broader In re Selenious Acid Litigation (Civil Action No. 2:24-cv-7791), a strategic procedural move that signals both the complexity and the commercial stakes of protecting pharmaceutical patent rights under US Patent No. US12150957B2. For patent attorneys, in-house IP counsel, and R&D professionals operating in the pharmaceutical space, this consolidation event offers valuable intelligence on multi-defendant litigation strategy, venue selection, and the growing enforcement landscape around injectable trace element formulations.

The Parties

The Patent at Issue

This critical case involved a single patent covering fundamental pharmaceutical formulation elements that are essential components of parenteral nutrition therapy:

• • US12150957B2 — Trace element compositions, specifically selenious acid formulations, and their methods of making and use.

Litigation Timeline & Legal Analysis

Litigation Timeline & Procedural History

Filing Date & Venue Significance: ARI’s selection of the District of New Jersey was deliberate and strategically sound. New Jersey is among the most active venues for Hatch-Waxman pharmaceutical patent litigation, given its proximity to major pharmaceutical corporate operations and its judges’ substantial experience with complex IP matters. The court’s Local Patent Rules provide a structured framework that both accelerates scheduling and rewards organized litigants.

Duration Analysis: The 21-day lifespan of Case No. 2:24-cv-11108 as a standalone action reflects not delay or weakness, but deliberate consolidation strategy. When a plaintiff files multiple coordinated actions simultaneously against different defendants asserting the same patent, consolidation into a single proceeding is both judicially efficient and strategically advantageous — centralizing discovery, claim construction, and scheduling while maintaining individual defendant accountability.

The consolidated matter, In re Selenious Acid Litigation (No. 2:24-cv-7791), was already pending prior to the December 2024 wave, suggesting an ongoing, escalating enforcement campaign by ARI rather than a reactive filing.

Outcome

Case No. 2:24-cv-11108 was closed on January 3, 2025, with the basis of termination recorded as Case Consolidated. No damages were assessed, and no injunctive relief was separately ordered at this procedural stage. The substantive infringement claims against Accord Healthcare, Ltd. were absorbed into the consolidated In re Selenious Acid Litigation proceeding, where they remain active under the umbrella case.

This outcome is purely procedural — it is not a victory or defeat for either party on the merits. The infringement action remains live.

Key Legal Issues

The underlying cause of action is patent infringement, most likely arising under the Hatch-Waxman Act framework (35 U.S.C. § 271(e)(2)), which governs pharmaceutical patent disputes triggered by Abbreviated New Drug Application (ANDA) filings. The simultaneous filing against twelve defendants on the same date strongly suggests that multiple ANDA filers submitted Paragraph IV certifications around the same period, triggering ARI’s coordinated enforcement response. US Patent No. US12150957B2, covering trace element compositions and methods of making and use, would likely face validity challenges grounded in **obviousness** (35 U.S.C. § 103) as well as potential **non-infringement** arguments.

The consolidation of thirteen related actions into a single proceeding carries several important legal implications, including unified claim construction, coordinated defense dynamics, and significant precedential weight for future cases involving US12150957B2.